Esperion Therapeutics Inc (ESPR) - Total Liabilities
Based on the latest financial reports, Esperion Therapeutics Inc (ESPR) has total liabilities worth $815.38 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Esperion Therapeutics Inc to track the company's year-over-year net asset growth rate.
Esperion Therapeutics Inc - Total Liabilities Trend (1999–2024)
This chart illustrates how Esperion Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Esperion Therapeutics Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Esperion Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Esperion Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Chengtian Weiye Technology Co Ltd
SHE:300689
|
China | CN¥117.15 Million |
|
Guangan
SHG:600979
|
China | CN¥8.87 Billion |
|
Aba Chemicals Corp
SHE:300261
|
China | CN¥2.13 Billion |
|
Covenant Logistics Group, Inc.
NYSE:CVLG
|
USA | $609.22 Million |
|
Huayi Brothers Media Corp
SHE:300027
|
China | CN¥2.12 Billion |
|
Changzhou Tronly New Electronic Materials Co Ltd
SHE:300429
|
China | CN¥1.55 Billion |
|
Wuhan Xianglong Power Industry Co Ltd
SHG:600769
|
China | CN¥293.09 Million |
|
Episil-Precision Inc
TW:3016
|
Taiwan | NT$1.83 Billion |
Liability Composition Analysis (1999–2024)
This chart breaks down Esperion Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ESPR market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Esperion Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Esperion Therapeutics Inc (1999–2024)
The table below shows the annual total liabilities of Esperion Therapeutics Inc from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $732.54 Million | +10.86% |
| 2023-12-31 | $660.79 Million | +15.58% |
| 2022-12-31 | $571.72 Million | -1.18% |
| 2021-12-31 | $578.53 Million | +28.74% |
| 2020-12-31 | $449.39 Million | +131.05% |
| 2019-12-31 | $194.50 Million | +202.33% |
| 2018-12-31 | $64.33 Million | +94.10% |
| 2017-12-31 | $33.14 Million | +99.53% |
| 2016-12-31 | $16.61 Million | +99.82% |
| 2015-12-31 | $8.31 Million | -15.09% |
| 2014-12-31 | $9.79 Million | +132.96% |
| 2013-12-31 | $4.20 Million | -82.99% |
| 2012-12-31 | $24.70 Million | +199.91% |
| 2011-12-31 | $8.24 Million | -34.96% |
| 2002-12-31 | $12.66 Million | +6.94% |
| 2001-12-31 | $11.84 Million | +16.26% |
| 2000-12-31 | $10.19 Million | +96.48% |
| 1999-12-31 | $5.18 Million | -- |
About Esperion Therapeutics Inc
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary h… Read more